Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Research and Markets: Next Generation Sequencing (NGS) Report 2013: How are NGS Technologies Revolutionizing the Way we Think About Healthcare?

10/10/2013 | 10:30am US/Eastern

Research and Markets (http://www.researchandmarkets.com/research/ddm37b/next_generation) has announced the addition of the "Next Generation Sequencing Report 2013" report to their offering.

The Next Generation Sequencing market is poised to reach $4.4B in 2018!

How are NGS Technologies Revolutionizing the Way we Think About Healthcare?

NGS technologies drive the way toward personalized medicine

Our analysis provides 2013-2018 market data, along with player market shares at both equipment and consumable levels. Moreover, positioning strategy of each supplier has been analyzed in the document.

Discover the NGS market's complex organization, splitted in four segments

The market segmentation is a tool used to provide a vision of the market. Based on technical and economic criteria, fours segments have been identified: research, forensics, diagnostics and consumer.

Until recently, uses of Next Generation Sequencing tools were limited to research (human whole genome, exome, small genome, targeted, transcriptome, RNA profiling, chIP-Seq, metagenomics).

Nowadays, NGS technologies have found applications mainly in two fields: clinical diagnostics and forensics.

Our investigation describes both current and future applications.

Next Generation Sequencing technologies overview

  • In April 2003, human genome project was declared complete. This first human genome sequencing took 13 years, mobilized 20000 researchers and cost $3B!
  • Since the early 2000s, sequencing technologies have come a long way from Sanger sequencing (also called 1st generation sequencing) used for the human genome project to the Next Generation Sequencing technologies available today.
  • By sequencing a large number of DNA molecules in parallel after PCR amplification, technology developers have been able to sharply increase machine throughput by a factor of 10, along with a steep price reduction.
  • The launch of a new detection method based on electrochemical detections was also a huge step forward for the sequencing world.
  • Today, based on these new technologies, we can sequence the whole human genome in less than three hours with one laboratory technician and a total cost around $1000.
  • Technologies under development are poised to extend the boundaries with a targeted sequencing cost of $100.
  • All technologies currently in use and those under development are presented in our report. Benchmarking is also presented for eight different sequencing applications.

New opportunities arise for cartridge makers

  • The wide adoption of NGS technology has changed the way NGS suppliers are generating revenue. A shift occurred in the sales mix, moving from instruments to consumables which have a higher gross margin than instruments.
  • This leads to an increase in revenue based on consumable sales.
  • The number of NGS Platforms used worldwide will exploded in the next several years and the run time will continue to decrease. Therefore, the market of NGS consumables will follow.

Report's key features

- 2013-2018 Next Generation Sequencing equipment market

- 2013-2018 Next Generation Sequencing consumable market

- Market segmentation which highlights current and future applications

- Overview of sequencing technologies and cartridges associated

- Detailed supply chain and business model analysis highlighting the major changes expected over next few years

- Company profiles of the main players

Report objectives

- Provide an overview of global NGS market both at equipment and consumable levels.

- Present main players and technologies involved

- Analyze both technical and market trends

- Focus on microfluidic consumable cartridges used for genome testing

- Supply Chain analysis

Key Topics Covered:

1. Executive summary

2. Introduction

3. Market data

4. Market segmentation

5. Next Generation Sequencing technologies overview

6. Value chain and supply chain

7. Market trends and challenges

8. Company profiles

Companies Mentioned

- 23andme

- Affymetrix

- Azco Biotech Inc

- Baseclear

- Base 4

- BGI-Shenzhen

- Completegenomics

- DNAvision

- Genia Technologies

- Genapsys

- GnuBIO

- Hitachi

- Illumina

- LaserGen

- NabSys

- Noblegen Biosciences

- Oxford Nanopore Technologies

- Pacific Biosciences

- Qiagen

- Roche 454

- Stratos Genomics Inc.

- Thermo Fisher Scientific

- TSMC

For more information visit http://www.researchandmarkets.com/research/ddm37b/next_generation

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


© Business Wire 2013
Latest news
Date Title
<1m ago CANAM ANNOUNCES THE LARGEST EB-5 PROJECT REPAYMENT TO DATE : Principal Repaid to 244 Investors in Full and on Time
<1m ago NEW PHARMACOLOGY STUDY FINDINGS HAVE BEEN REPORTED BY INVESTIGATORS AT F. HOFFMANN-LA ROCHE (GENOTOXICITY TESTING OF PEPTIDES : Folate deprivation as...
<1m ago HORIZON BANCORP : posts 3Q profit
3m ago Weatherford misses Street 3Q forecasts
4m ago H LUNDBECK A/S : Investigators from H. Lundbeck AS Target Pharmacology (Probing for Improved Potency and In Vivo Bioavailability of Excitatory Amino Acid Transporter...
5m ago Statement by UFCW Canada National President Paul Meinema on the Shooting at Parliament Hill and the War Memorial
5m ago SORRENTO THERAPEUTICS : Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel
5m ago INFINITY PHARMACEUTICALS : Reports Topline Data from Phase 2a Exploratory Study of Duvelisib in Patients with Mild, Allergic Asthma
5m ago IMS HEALTH : to Announce Third-Quarter 2014 Results On October 24, 2014
5m ago AGL ENERGY : Annual General Meeting 2014
Latest news
Advertisement
Hot News 
BOULDER BRANDS : Announces Preliminary Third Quarter 2014 Results
TUPPERWARE BRANDS : Reports Third Quarter Results
WILLBROS : Elects John T. McNabb, II Chief Executive Officer
CLICKSOFTWARE TECHNOLOGIES : Appoints New CFO
ALTISOURCE PORTFOLIO SOLUTIONS : INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Altisource Portfolio Solutions S.A.
Most Read News
27m ago AT&T revenue misses forecasts as more customers bring own phones
1h ago TERADYNE : beats Street 3Q forecasts
1h ago EXELON : ICC Approves ComEd’s Grand Prairie Gateway Project
1h ago ATMEL : Patent Issued for Apparatus and Method for Increasing the Quantity of Discrete Electronic Components in an Integrated Circuit Package
1h ago TESORO LOGISTICS : Announces Pricing of $1.3 Billion of Senior Notes
Most recommended articles
5m ago EUR/USD TECHNICAL ANALYSIS : Short Entry Setup Established
6m ago USD/JPY TECHNICAL ANALYSIS : Upside Momentum Lacking
27m ago AT&T revenue misses forecasts as more customers bring own phones
33m ago Plant revamps push UK car production down 3 percent in September
41m ago Talent shortage drives pay up in UK financial services, tech sectors
Dynamic quotes  
ON
| OFF